SU1433413A3 - Способ получени замещенного имидазо @ 1,5- @ пиридина или его фармацевтически приемлемой соли - Google Patents
Способ получени замещенного имидазо @ 1,5- @ пиридина или его фармацевтически приемлемой соли Download PDFInfo
- Publication number
- SU1433413A3 SU1433413A3 SU853917403A SU3917403A SU1433413A3 SU 1433413 A3 SU1433413 A3 SU 1433413A3 SU 853917403 A SU853917403 A SU 853917403A SU 3917403 A SU3917403 A SU 3917403A SU 1433413 A3 SU1433413 A3 SU 1433413A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- pyridine
- compound
- imidazo
- solution
- acceptable salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 31
- -1 cyano, carboxy Chemical group 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 7
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical class C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- ZRBDYBQIBBZJBE-UHFFFAOYSA-N 4-imidazo[1,5-a]pyridin-5-ylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC2=CN=CN12 ZRBDYBQIBBZJBE-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- UBSPPJXJSOOGNV-UHFFFAOYSA-N 4-imidazo[1,5-a]pyridin-5-ylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC2=CN=CN12 UBSPPJXJSOOGNV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 2
- 108010078554 Aromatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- AWZFWCYKSQWHBU-UHFFFAOYSA-N ethyl 4-(6-cyanopyridin-2-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC(C#N)=N1 AWZFWCYKSQWHBU-UHFFFAOYSA-N 0.000 description 2
- WERJSLJYUGFUPH-UHFFFAOYSA-N ethyl 4-[6-(aminomethyl)pyridin-2-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC(CN)=N1 WERJSLJYUGFUPH-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- MMLVHQNFESMBKX-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)formamide Chemical compound O=CNCC1=CC=CC=N1 MMLVHQNFESMBKX-UHFFFAOYSA-N 0.000 description 2
- PHHKMTVZAKTCIA-UHFFFAOYSA-N n-tert-butyl-4-imidazo[1,5-a]pyridin-5-ylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C1=CC=CC2=CN=CN12 PHHKMTVZAKTCIA-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JVORFZLMRBKKDI-UHFFFAOYSA-N 4-imidazo[1,5-a]pyridin-5-ylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC2=CN=CN12 JVORFZLMRBKKDI-UHFFFAOYSA-N 0.000 description 1
- KGFCWLPCVCVTAV-UHFFFAOYSA-N 4-imidazo[1,5-a]pyridin-5-ylbenzoic acid;hydrochloride Chemical compound Cl.C1=CC(C(=O)O)=CC=C1C1=CC=CC2=CN=CN12 KGFCWLPCVCVTAV-UHFFFAOYSA-N 0.000 description 1
- BVMJNMTURCZGHG-UHFFFAOYSA-N 5-(4-bromophenyl)imidazo[1,5-a]pyridine Chemical compound C1=CC(Br)=CC=C1C1=CC=CC2=CN=CN12 BVMJNMTURCZGHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- QKYILQOKUXDPHM-UHFFFAOYSA-N ethyl 4-[6-(formamidomethyl)pyridin-2-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC(CNC=O)=N1 QKYILQOKUXDPHM-UHFFFAOYSA-N 0.000 description 1
- NNSDTRFALMDPPW-UHFFFAOYSA-N ethyl 4-pyridin-2-ylbenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=N1 NNSDTRFALMDPPW-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/622,421 US4617307A (en) | 1984-06-20 | 1984-06-20 | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1433413A3 true SU1433413A3 (ru) | 1988-10-23 |
Family
ID=24494112
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU853917403A SU1433413A3 (ru) | 1984-06-20 | 1985-06-19 | Способ получени замещенного имидазо @ 1,5- @ пиридина или его фармацевтически приемлемой соли |
SU864027754A SU1436878A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их кислотно-аддитивных солей,или их стереоизомеров,или смеси стереоизомеров |
SU864027757A SU1436880A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их стереоизомеров,или смеси стереоизомеров,или их кислотно-аддитивных солей |
SU864027758A SU1443802A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений, или их стереоизомеров, или смеси стереоизомеров, или их кислотно-аддитивных солей |
SU864027755A SU1436879A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их стереоизомеров,или смеси стереоизомеров,или их кислотно-аддитивных солей |
SU864027756A SU1482530A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени производных имидазола, их стереоизомеров, смеси стереоизомеров или их фармацевтически приемлемых солей |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU864027754A SU1436878A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их кислотно-аддитивных солей,или их стереоизомеров,или смеси стереоизомеров |
SU864027757A SU1436880A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их стереоизомеров,или смеси стереоизомеров,или их кислотно-аддитивных солей |
SU864027758A SU1443802A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений, или их стереоизомеров, или смеси стереоизомеров, или их кислотно-аддитивных солей |
SU864027755A SU1436879A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени замещенных азотсодержащих бициклических соединений,или их стереоизомеров,или смеси стереоизомеров,или их кислотно-аддитивных солей |
SU864027756A SU1482530A3 (ru) | 1984-06-20 | 1986-07-02 | Способ получени производных имидазола, их стереоизомеров, смеси стереоизомеров или их фармацевтически приемлемых солей |
Country Status (31)
Country | Link |
---|---|
US (1) | US4617307A (es) |
EP (1) | EP0165904B1 (es) |
JP (1) | JPS6112688A (es) |
KR (1) | KR900008566B1 (es) |
AT (1) | ATE62415T1 (es) |
AU (1) | AU589565B2 (es) |
BG (7) | BG60262B2 (es) |
CA (1) | CA1276633C (es) |
CS (1) | CS268672B2 (es) |
CY (1) | CY1750A (es) |
DD (1) | DD237510A5 (es) |
DE (1) | DE3582452D1 (es) |
DK (1) | DK170302B1 (es) |
DZ (1) | DZ799A1 (es) |
ES (6) | ES8702406A1 (es) |
FI (1) | FI80694C (es) |
GR (1) | GR851487B (es) |
HK (1) | HK23494A (es) |
HU (1) | HU202529B (es) |
IE (1) | IE58070B1 (es) |
IL (1) | IL75546A (es) |
MA (1) | MA20459A1 (es) |
MX (1) | MX9203369A (es) |
NO (1) | NO162467C (es) |
NZ (1) | NZ212483A (es) |
PH (1) | PH23390A (es) |
PL (6) | PL145348B1 (es) |
PT (1) | PT80661B (es) |
RO (1) | RO92583A (es) |
SU (6) | SU1433413A3 (es) |
ZA (1) | ZA854615B (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4728645A (en) * | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
GB8510541D0 (en) * | 1985-04-25 | 1985-05-30 | Wyeth John & Brother Ltd | Heterocyclic compounds |
US5171858A (en) * | 1985-06-05 | 1992-12-15 | Schering A.G. | Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines |
US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
US4749713A (en) * | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
US4937250A (en) * | 1988-03-07 | 1990-06-26 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
IL83163A (en) * | 1986-07-18 | 1991-06-10 | Erba Carlo Spa | Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them |
GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
US5066656A (en) * | 1989-11-01 | 1991-11-19 | Janssen Pharmaceutica N.V. | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives |
MTP1076B (en) * | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
US5162337A (en) * | 1990-10-05 | 1992-11-10 | Merck & Co., Inc. | Animal growth promotion |
CA2066369A1 (en) * | 1991-04-19 | 1992-10-20 | Alex Elbrecht | Control of sex differentiation in fish |
CH683151A5 (de) * | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
JPH05176659A (ja) * | 1991-04-26 | 1993-07-20 | Merck & Co Inc | 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法 |
AU2356195A (en) * | 1994-04-14 | 1995-11-10 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
US5587392A (en) * | 1994-05-27 | 1996-12-24 | Mochida Pharmaceutical Co., Ltd. | Azolyl methyl phenyl derivatives having aromatase inhibitory activity |
DE4432106A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
CA2494345C (en) * | 2002-07-30 | 2011-11-29 | Novartis Ag | Combination of an aromatase inhibitor with a bisphosphonate |
DE60307483T2 (de) * | 2002-08-07 | 2007-07-05 | Novartis Ag | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
ATE398124T1 (de) * | 2002-11-18 | 2008-07-15 | Novartis Pharma Gmbh | Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron |
WO2005007627A1 (ja) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤 |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
TW200611898A (en) * | 2004-05-28 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
TW200616623A (en) * | 2004-05-28 | 2006-06-01 | Speedel Experimenta Ag | Organic compounds |
GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
JP2009538323A (ja) * | 2006-05-26 | 2009-11-05 | ノバルティス アクチエンゲゼルシャフト | アルドステロン合成酵素および/または11β−ヒドロキシラーゼ阻害剤 |
KR101149274B1 (ko) | 2006-07-20 | 2012-05-29 | 노파르티스 아게 | Cετρ 억제제로서의 아미노-피페리딘 유도체 |
WO2008027284A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
PE20090982A1 (es) | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
EP2229356B1 (en) | 2007-12-03 | 2011-10-12 | Novartis AG | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
BRPI1011657A2 (pt) | 2009-05-28 | 2019-04-16 | Novartis Ag | derivados aminopropiônicos substituídos como inibidores de neprilisina |
EA201101672A1 (ru) | 2009-05-28 | 2012-06-29 | Новартис Аг | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
TWI518073B (zh) * | 2011-06-14 | 2016-01-21 | 美國禮來大藥廠 | 醛固酮合成酶抑制劑 |
ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
AP2014007762A0 (en) | 2012-01-17 | 2014-07-31 | Novartis Ag | New forms and salts of a dihydropyrrolo[1,2C]imidazolyl aldosterone synthase or aromatase inhibitor |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
US9340582B2 (en) | 2013-07-25 | 2016-05-17 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
HUE054248T2 (hu) * | 2015-01-29 | 2021-08-30 | Recordati Ag | Eljárás kondenzált imidazo-származékok elõállítására |
GB201511790D0 (en) * | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
JP2016074729A (ja) * | 2015-12-31 | 2016-05-12 | 国立大学法人 千葉大学 | イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
CN114853755A (zh) * | 2016-10-27 | 2022-08-05 | 达米安制药股份公司 | 醛固酮合酶抑制剂 |
WO2018078049A1 (en) | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
BR112020022173A2 (pt) | 2018-05-03 | 2021-02-02 | Damian Pharma Ag | r-fadrozol para uso no tratamento de aldostonerismo |
JP2022507958A (ja) | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害薬としての環状四量体化合物 |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5124517B1 (es) * | 1971-03-15 | 1976-07-24 | ||
FR2449689A1 (fr) * | 1979-02-20 | 1980-09-19 | Logeais Labor Jacques | Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique |
CA1250844A (en) * | 1981-06-22 | 1989-03-07 | Neville Ford | Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application |
US4444775A (en) * | 1981-06-22 | 1984-04-24 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridines |
US4409226A (en) * | 1981-10-05 | 1983-10-11 | Schering Corporation | Imidazo[1,5-a]pyridines |
US4361567A (en) * | 1981-10-05 | 1982-11-30 | Schering Corporation | Treatment of peptic ulcer disease |
US4588732A (en) * | 1982-12-21 | 1986-05-13 | Ciba-Geigy Corporation | Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors |
US4470986A (en) * | 1982-12-21 | 1984-09-11 | Ciba-Geigy Corporation | Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors |
-
1984
- 1984-06-20 US US06/622,421 patent/US4617307A/en not_active Expired - Lifetime
-
1985
- 1985-06-17 DE DE8585810279T patent/DE3582452D1/de not_active Expired - Lifetime
- 1985-06-17 EP EP85810279A patent/EP0165904B1/de not_active Expired - Lifetime
- 1985-06-17 FI FI852399A patent/FI80694C/fi not_active IP Right Cessation
- 1985-06-17 AT AT85810279T patent/ATE62415T1/de not_active IP Right Cessation
- 1985-06-18 CA CA000484263A patent/CA1276633C/en not_active Expired - Lifetime
- 1985-06-18 IL IL75546A patent/IL75546A/xx not_active IP Right Cessation
- 1985-06-18 DZ DZ850130A patent/DZ799A1/fr active
- 1985-06-18 GR GR851487A patent/GR851487B/el unknown
- 1985-06-18 CS CS854449A patent/CS268672B2/cs not_active IP Right Cessation
- 1985-06-19 KR KR1019850004323A patent/KR900008566B1/ko not_active IP Right Cessation
- 1985-06-19 NZ NZ212483A patent/NZ212483A/xx unknown
- 1985-06-19 PT PT80661A patent/PT80661B/pt unknown
- 1985-06-19 BG BG70749A patent/BG60262B2/xx unknown
- 1985-06-19 DK DK277685A patent/DK170302B1/da not_active IP Right Cessation
- 1985-06-19 HU HU852417A patent/HU202529B/hu unknown
- 1985-06-19 NO NO852474A patent/NO162467C/no unknown
- 1985-06-19 PH PH32427A patent/PH23390A/en unknown
- 1985-06-19 ES ES544344A patent/ES8702406A1/es not_active Expired
- 1985-06-19 IE IE152085A patent/IE58070B1/en not_active IP Right Cessation
- 1985-06-19 AU AU43857/85A patent/AU589565B2/en not_active Expired
- 1985-06-19 RO RO85119210A patent/RO92583A/ro unknown
- 1985-06-19 SU SU853917403A patent/SU1433413A3/ru active
- 1985-06-19 ZA ZA854615A patent/ZA854615B/xx unknown
- 1985-06-19 MA MA20686A patent/MA20459A1/fr unknown
- 1985-06-20 PL PL1985259304A patent/PL145348B1/pl unknown
- 1985-06-20 PL PL1985259307A patent/PL145105B1/pl unknown
- 1985-06-20 PL PL1985259303A patent/PL145103B1/pl unknown
- 1985-06-20 PL PL1985254099A patent/PL145087B1/pl unknown
- 1985-06-20 JP JP60133167A patent/JPS6112688A/ja active Granted
- 1985-06-20 DD DD85277587A patent/DD237510A5/de not_active IP Right Cessation
- 1985-06-20 PL PL1985259305A patent/PL145814B1/pl unknown
- 1985-06-20 PL PL1985259306A patent/PL145104B1/pl unknown
-
1986
- 1986-05-30 ES ES555540A patent/ES8801262A1/es not_active Expired
- 1986-05-30 ES ES555539A patent/ES8802155A1/es not_active Expired
- 1986-05-30 ES ES555542A patent/ES8802049A1/es not_active Expired
- 1986-05-30 ES ES555541A patent/ES8800681A1/es not_active Expired
- 1986-05-30 ES ES555538A patent/ES8802048A1/es not_active Expired
- 1986-07-02 SU SU864027754A patent/SU1436878A3/ru active
- 1986-07-02 SU SU864027757A patent/SU1436880A3/ru active
- 1986-07-02 SU SU864027758A patent/SU1443802A3/ru active
- 1986-07-02 SU SU864027755A patent/SU1436879A3/ru active
- 1986-07-02 SU SU864027756A patent/SU1482530A3/ru active
-
1992
- 1992-06-25 MX MX9203369A patent/MX9203369A/es unknown
- 1992-10-22 BG BG97010A patent/BG60306B2/bg unknown
- 1992-10-22 BG BG97013A patent/BG60353B2/bg unknown
- 1992-10-22 BG BG97012A patent/BG60352B2/bg not_active Expired - Lifetime
- 1992-10-22 BG BG97009A patent/BG60305B2/bg unknown
- 1992-10-22 BG BG97011A patent/BG60307B2/xx unknown
-
1993
- 1993-11-11 BG BG98213A patent/BG60402B2/bg unknown
-
1994
- 1994-03-17 HK HK234/94A patent/HK23494A/xx not_active IP Right Cessation
- 1994-06-03 CY CY175094A patent/CY1750A/xx unknown
Non-Patent Citations (1)
Title |
---|
Эльдерфилд Р. Гетероциклические соединени . - М.: Иностранна литература, 1954, т. V, с. 217. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1433413A3 (ru) | Способ получени замещенного имидазо @ 1,5- @ пиридина или его фармацевтически приемлемой соли | |
WO2004017908A2 (en) | Calcium receptor modulating compound and use thereof | |
JP2002513024A (ja) | 胃酸分泌を阻害するイミダゾピリジン誘導体 | |
EP0172096A1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
JP3281320B2 (ja) | 神経伝達物質放出増強薬としての新規な非環式アミド類 | |
ITMI961732A1 (it) | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze e in particolare dell'alcoolismo | |
US4746655A (en) | Fused aromatic-spiropiperidine oxazepinones(and thiones) | |
JPS63174988A (ja) | ヘテロアリール3‐オキソ‐プロバンニトリル誘導体及びその製造方法 | |
US5565463A (en) | 9-subtituted-8-unsubstituted-9-deazaguanines | |
US5008265A (en) | 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same | |
WO2014020101A1 (fr) | Derives de griseofulvine | |
US4866056A (en) | Benzazepines and methods therefor | |
EP0008249B1 (fr) | Dérivés de fluorènes et fluoranthènes, leur procédé de préparation et leur application en thérapeutique | |
IE913598A1 (en) | Heterocyclic compounds | |
JPS61286367A (ja) | ベンズアゼピン誘導体 | |
FR2593818A1 (fr) | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique | |
SU1169538A3 (ru) | Способ получени трициклических соединений | |
US3852292A (en) | 2-(pyridyl)-imidazole-4,5-dicarboxylic acid and derivatives | |
US4180581A (en) | N-9,10-dihydrolysergyl-m-aminobenzoic acid amide derivative | |
US5057526A (en) | Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo-[3,2-f]benzoxazole-6-ones | |
Das et al. | Bromo-lactamization of isoxazole via neighboring group participation: toward spiro-isoxazoline γ-and δ-lactams | |
IE50006B1 (en) | Derivatives of tetrahydropyrid-4-yl-indole | |
EP0001585B1 (de) | Piperazino-pyrrolobenzodiazepine, Verfahren zu ihrer Herstellung sowie pharmazeutische Präparate enthaltend diese Verbindungen | |
US3772299A (en) | P'-alkoxy-ergotamines | |
US3595874A (en) | 3,4,5,10-tetrahydroazepino(2,3-b)indol-5a (2h)-ols |